ERBITUX 2mg / ml infusion solution medication leaflet

L01XC06 cetuximab • Antineoplastic and immunomodulating agents | Other antineoplastic agents | Monoclonal antibodies

Cetuximab is a monoclonal antibody used in the treatment of certain types of cancer, such as metastatic colorectal cancer and head and neck cancer. It works by blocking the epidermal growth factor receptor (EGFR), thereby inhibiting the growth and division of cancer cells.

Cetuximab is administered intravenously and is used either alone or in combination with other therapies, such as chemotherapy or radiation therapy. It is particularly indicated in patients with tumors that do not have KRAS gene mutations, as its effectiveness depends on this genetic factor.

Side effects may include skin reactions (acne-like rash), fatigue, nausea, diarrhea, hypomagnesemia, or severe allergic reactions. It is contraindicated in patients with hypersensitivity to cetuximab or other murine-derived proteins.

General data about ERBITUX 2mg / ml

Substance: cetuximab

Date of last drug list: 01-07-2013

Commercial code: W43295001

Concentration: 2mg / ml

Pharmaceutical form: infusion solution

Quantity: 1

Product type: original

Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.

Concentrations available for cetuximab

2mg/ml, 5mg/ml